|

Repotrectinib Clinical Trials

4 actively recruiting trials across 1 location

Also known as: BMS-986472, TPX-0005

Pipeline

Phase 1: 1Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • MedSIR1
  • Instituto Oncológico Dr Rosell1
  • Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer1

Indications

  • Cancer4
  • Lung Cancer3
  • NSCLC2
  • ROS1 Gene Rearrangement1
  • NSCLC, Stage III1

Other3 trials

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
Phase 1
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Phase 2
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Phase 2

New York, New York1 trial

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.